Sudeep Pharma IPO Analyzed

Sudeep Pharma, a company that makes ingredients for medicines, food, and supplements, recently completed its Initial Public Offering (IPO). Investors showed strong interest, bidding for almost all the shares offered. This analysis breaks down the key details of the IPO and what it means for the company’s future.

Key Points

• Investors bid for 99% of shares offered in the Sudeep Pharma IPO.
• The IPO was heavily subscribed, indicating strong market confidence.
• The company raised ₹268.49 crore from anchor investors before the IPO.
• The IPO aims to fund new machinery and general corporate expenses.
• Sudeep Pharma focuses on pharmaceutical ingredients and specialty nutrition.
• India contributes 41% of the company’s sales, with significant exports.

The IPO was for a new issue of shares worth up to ₹95 crore, plus an existing sale of 1,34,90,726 shares. The price range for these shares was between ₹563 and ₹593. Investors responded by bidding for 99 crore shares, which is almost all the shares the company was offering.

The money raised by Sudeep Pharma is going towards two main things. First, ₹75.8 crore will be used to buy new equipment for a production plant in Nandesari. Second, the remaining funds will be used for general business expenses. This shows the company is growing and investing in its future.

Sudeep Pharma is divided into two parts. The first part, called the Pharmaceutical, Food, and Nutrition vertical, makes basic ingredients like calcium, zinc, and iron. These are used in medicines, food, and supplements. The second part, the Specialty Ingredients vertical, uses technology to create more advanced ingredient systems, including encapsulated and spray-dried minerals.

In the first three months of the financial year 2026 (Q1 FY26), the company made 66.43% of its revenue from the pharmaceutical and food parts and 33.57% from the specialty ingredients. Importantly, 41.32% of the company’s sales come from India, while 58.68% are exported. Ahead of the IPO, anchor investors bought shares worth ₹268.49 crore.

For the period ending June 30, 2025, Sudeep Pharma reported a profit of ₹30.81 crore and sales of ₹124.92 crore. This demonstrates the company’s solid financial performance and growth potential.

Ultimately, this IPO represents a significant step for Sudeep Pharma, highlighting investor confidence and setting the stage for future expansion.